Evidence-based guides on metabolic health, hormones, peptides, and longevity. Understand your biology and make better decisions.
See how your biomarkers, risk factors, and goals translate into next steps.
Most adults discover metabolic dysfunction long after symptoms appear. The clinical criteria for metabolic syndrome give you a framework for spotting it years earlier — using markers your annual physical already measures.
Read article →
Low testosterone isn't one problem with one fix. A plain-English look at the hormones involved, what each therapy does, and how a provider decides between them.
Read article →
The science moved on from the 2002 scare. An honest explanation of estrogen, progesterone, and how to think about the risks of HRT clearly rather than fearfully.
Read article →
What the published research actually says about each compound — separated from the social-media noise. Where evidence is strong and where it's still preliminary.
Read article →
The threshold for "pre-diabetes" sits at 5.7 — but the disease process starts earlier. Here's what the trajectory typically looks like, and why early action changes the curve.
Read article →Most people who develop type 2 diabetes, heart disease, or stroke didn't get there overnight. They got there over a decade or two of slowly drifting metabolic markers — markers that were already on the lab panel of their annual physical, but that nobody flagged because each one, alone, was "still in range." Metabolic syndrome is the recognition that these markers cluster, and that the cluster itself is the disease, long before any individual marker becomes a diagnosis.
Metabolic syndrome isn't a single disease. It's a clinically-defined cluster of five common findings that, when three or more co-occur, identify someone whose risk for cardiovascular disease and type 2 diabetes is meaningfully elevated — even if no single finding has crossed into a "real" diagnosis yet.
The criteria most clinicians use come from the National Cholesterol Education Program's Adult Treatment Panel III (ATP III), updated in 2005. The framework asks: looking at the most common modifiable risks, how many is this person carrying?
The threshold is ≥40 inches for men, ≥35 inches for women. Waist measurement is preferred over BMI because central fat — the kind that sits around the abdominal organs — is metabolically more disruptive than fat distributed elsewhere. Two people with the same BMI can have very different metabolic profiles depending on where the fat lives.
If waist measurement isn't available, BMI ≥30 is sometimes used as a proxy. It's imperfect: a muscular athlete can carry BMI 31 with normal waist circumference, and a sedentary office worker can carry BMI 26 with abdominal obesity. Waist is the more reliable signal.
Triglycerides are how your body stores excess calories — particularly excess refined carbohydrates and alcohol — for later use. Elevated fasting triglycerides indicate that the system is overwhelmed: more incoming energy than current capacity to store or burn it, often combined with insulin resistance.
Triglycerides above 150 are a strong signal of metabolic strain even when other lipid numbers (LDL, total cholesterol) look fine. Some clinicians weight this marker more heavily than the formal criteria do, because high triglycerides are tightly correlated with the underlying insulin resistance that drives the rest of the syndrome.
The threshold is <40 mg/dL for men, <50 mg/dL for women. HDL is the lipoprotein that ferries cholesterol away from artery walls. Low HDL doesn't directly cause cardiovascular disease, but it's a reliable marker of metabolic dysfunction — the same processes that drive insulin resistance and high triglycerides also suppress HDL production.
Low HDL is one of the markers that's hardest to move with diet alone. Aerobic exercise, smoking cessation, and weight loss all help; statins typically don't.
The metabolic syndrome BP cutoff (≥130/85) is intentionally lower than the cutoff for clinical hypertension diagnosis. The point is to capture people whose pressure is rising even before they meet the criteria for a "BP diagnosis." Blood pressure rising over time tracks tightly with insulin resistance and visceral fat — both upstream drivers in the same cluster.
Note: if someone is taking antihypertensive medication, that counts as meeting the criterion, regardless of what the current reading is. The medication is treating the underlying condition; the underlying condition is what the syndrome is measuring.
The original criterion is fasting glucose ≥100 mg/dL. In practice, many clinicians substitute hemoglobin A1c ≥5.7 — the "pre-diabetes" range — because A1c reflects average glucose over 2-3 months and isn't sensitive to whether the patient actually fasted properly before the lab draw.
This marker is the closest one to becoming a "real" diabetes diagnosis. By the time fasting glucose hits 126 or A1c hits 6.5, the person has type 2 diabetes by definition. Before that, the trajectory has typically been visible on labs for 3–7 years if anyone was watching.
The "three of five" rule isn't arbitrary. Cohort studies (the most-cited being the third National Health and Nutrition Examination Survey, NHANES III) found that the risk for cardiovascular events and progression to type 2 diabetes climbed sharply at the 3-criterion threshold, while people with only one or two criteria had risk profiles much closer to people with zero criteria.
So the cluster matters more than any single marker. Someone with elevated triglycerides alone has a different prognosis than someone with elevated triglycerides plus low HDL plus rising glucose — the second person is on a metabolic trajectory the first person isn't.
For someone meeting the ATP III definition, the published natural history (Lakka et al., JAMA 2002, and subsequent meta-analyses) is roughly:
None of these are "you will get this." They're statistical elevations of risk over baseline. People with metabolic syndrome do not all progress to diabetes; people without it do not all stay disease-free. But the cluster moves the curves enough that early identification meaningfully changes the population-level outcomes.
The good news in the metabolic syndrome literature is that the cluster is responsive to intervention — usually more responsive than any single marker treated in isolation. Studies consistently show:
If you have access to your most recent annual physical labs, you already have most of what you need to estimate where you sit on this framework. Look for: waist circumference (or BMI as a proxy), fasting triglycerides, HDL, blood pressure, and either fasting glucose or A1c.
Count the criteria. If you're carrying three or more, the most useful next step is a conversation with your primary care provider — not because you have an emergency, but because the trajectory is real and acting on it earlier is meaningfully better than acting on it later.
Reach Peak Life's Longevity Score includes a metabolic syndrome screen as part of its scoring engine. If you'd like to see where your numbers land — and what the most modifiable lever in your particular profile is — the calculator takes about 5 minutes. Your data is processed entirely in your browser and isn't sent to any server unless you explicitly opt to receive your report by email.
5 minutes. Browser-only. Built around the same evidence base this article is.
Start your assessment →"Low testosterone" gets treated like a single problem with a single fix. It isn't. The same set of symptoms — low energy, reduced drive, slower recovery, weight that won't shift — can come from genuinely low hormone production, from lifestyle factors that suppress it, or from something else entirely. And when therapy is appropriate, there's more than one tool. This is a plain-English explanation of the hormones involved, what each therapy actually does, and how a good provider decides between them.
Testosterone production runs through a feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases GnRH, which tells the pituitary to release two signaling hormones — LH and FSH. LH then tells the testes to produce testosterone; FSH supports sperm production. The body constantly measures circulating testosterone and estradiol and dials the upstream signals up or down to hold the system in balance.
This matters because every men's hormone therapy acts on a different part of this loop — and that's exactly what makes them behave differently. Replacing testosterone from the outside is not the same as nudging your own production to run higher, even if the number on the lab report ends up similar.
Exogenous testosterone — delivered as an injection, cream, or pellet — restores circulating levels directly. It is the most predictable and best-studied option, with decades of clinical use and the recent TRAVERSE cardiovascular safety data (Lincoff et al., 2023) providing reassurance on a question that had been debated for years.
The trade-off is built into the biology. Because your body senses the higher testosterone, it turns down its own upstream LH and FSH signaling. Endogenous production drops, the testes shrink modestly over time, and sperm production is reduced — often significantly. For a man whose family is complete, this is usually a non-issue. For a man under 40 who may want children, it is the single most important thing to discuss before starting, and it's the reason the next therapy exists.
Enclomiphene works in the opposite direction. Rather than replacing testosterone, it blocks estrogen feedback at the hypothalamus. With less estrogen "braking" the system, the hypothalamus increases GnRH, the pituitary releases more LH and FSH, and the testes produce more of your own testosterone. The HPG axis stays switched on, and sperm production is preserved — the key clinical distinction from testosterone replacement.
Enclomiphene is the trans-isomer of clomiphene, isolated from the isomer associated with mood and vision side effects. In published trials (Wiehle et al., 2014; Kim et al., 2016) it raised total testosterone meaningfully in men with secondary hypogonadism while preserving sperm counts. It's taken as a daily oral capsule, which many men prefer over injections. It is used off-label for symptomatic hypogonadism and is available through 503A compounding pharmacies; it is not FDA-approved as a commercial product, though it was studied and reviewed (not approved) by the FDA in 2016.
One important nuance: enclomiphene works best for secondary hypogonadism, where the testes still function but upstream signaling is low. It is less effective for primary hypogonadism, where the testes themselves aren't responding. Checking LH and FSH alongside testosterone on your labs is what tells a provider which situation you're in.
hCG mimics LH directly, stimulating the testes while bypassing the hypothalamus and pituitary. It's sometimes used on its own in younger men prioritizing fertility, and sometimes added to a testosterone protocol specifically to maintain testicular function during treatment. Anastrozole is an aromatase inhibitor that reduces the conversion of testosterone to estrogen; it's used selectively — never by default — when labs show elevated estradiol causing symptoms like water retention or breast tenderness. Both are add-ons to a base protocol, prescribed only when clinically warranted.
The major guidelines are consistent that several non-pharmaceutical factors move testosterone meaningfully, and a responsible program addresses them first:
None of these are quick fixes, but all are zero-risk and frequently move the number enough that the question of therapy answers itself.
The right therapy depends on age, fertility goals, baseline labs, and which part of the HPG axis is the real bottleneck. A 28-year-old with secondary hypogonadism who wants children in five years has a different optimal protocol than a 55-year-old whose family is complete and whose main complaints are fatigue and recovery. A licensed prescriber working from a full panel — LH, FSH, total and free testosterone, estradiol, and SHBG — is the only way to make this decision well. The existence of multiple options isn't a menu to pick from; it's a recognition that "low T" is a symptom and a number, and the best treatment depends on what's causing them.
If you've addressed the lifestyle levers and your numbers are still consistently low — or you have documented symptoms with values in the 250–300 range — Reach Peak Life's Men's Health program connects you with independent prescribers for evaluation. Therapy is prescribed only when criteria are met, and only with ongoing lab monitoring.
Provider-supervised testosterone and enclomiphene for men whose labs and symptoms meet clinical criteria — protocol selected by your prescriber based on your goals, fertility considerations, and baseline labs.
Learn about Men's Health →For two decades, a single misread study scared a generation of women away from hormone therapy. The science has moved on considerably since then, and the current consensus is more nuanced — and for many women, more reassuring. This is a clear explanation of the hormones involved in perimenopause and menopause, what estrogen and progesterone each do, and how to think about the risks honestly rather than fearfully.
Perimenopause is the transition leading up to menopause — often starting in the 40s — when ovarian hormone production becomes erratic before it declines. Estrogen and progesterone don't simply fade; they fluctuate, sometimes wildly, which is why symptoms in this phase can feel unpredictable. Menopause itself is defined as 12 consecutive months without a period, after which estrogen settles at a persistently low level.
The symptoms most women notice — hot flashes, night sweats, disrupted sleep, mood changes, brain fog, vaginal dryness, and shifts in libido — trace back to this hormonal change. They're not "in your head," and they're not something to simply endure. They're a physiological response to falling hormones, which is precisely what hormone therapy addresses.
Estradiol is the primary estrogen the ovaries produce less of during this transition. Replacing it is the most effective treatment available for vasomotor symptoms — hot flashes and night sweats — and it also supports sleep, mood, and genitourinary comfort. Beyond symptom relief, estrogen therapy helps preserve bone density, reducing the risk of osteoporosis and fractures after menopause.
How estrogen is delivered matters for safety. Transdermal estradiol — a cream or patch absorbed through the skin — carries a lower risk of blood clots than oral estrogen, because it bypasses first-pass metabolism in the liver. For this reason it's often preferred for women with clot risk factors, migraine with aura, or higher BMI. The form and dose are decisions a provider makes with your individual risk profile in mind.
If you have a uterus and take estrogen, you also need progesterone. Estrogen alone stimulates the uterine lining (the endometrium); unopposed, that stimulation raises the risk of endometrial hyperplasia and cancer over time. Progesterone balances estrogen and protects the lining — which is why estrogen and progesterone are most commonly prescribed together as a bundle for women with a uterus.
Progesterone has a second, welcome effect for many women: taken at night, it often supports sleep and a sense of calm. It's typically a capsule, dosed in the evening. Women who've had a hysterectomy generally don't need progesterone and may take estrogen alone.
Much of the fear around hormone therapy traces to the 2002 Women's Health Initiative (WHI). Later re-analysis told a more nuanced story than the headlines did. Several points are now broadly accepted:
None of this means hormone therapy is right for everyone — it isn't. It means the decision deserves an individualized conversation rather than a blanket fear inherited from a misread study.
Menopausal hormone therapy is frequently started based on symptoms, with labs (estradiol, FSH, thyroid, metabolic markers) used to personalize the plan and rule out other causes. It is generally avoided in women with active or prior hormone-sensitive cancer, unexplained vaginal bleeding, a history of blood clots or stroke, or active liver disease, and used with added caution in women with migraine with aura or a long interval since menopause. A licensed provider determines eligibility individually — not everyone qualifies, and an honest program says so.
Reach Peak Life's Women's Health program connects you with independent prescribers for evaluation and, when appropriate, provider-supervised estrogen and progesterone — as a bundle or individually — with the form and route chosen for your risk profile.
Provider-supervised estrogen and progesterone for perimenopause and menopause, prescribed only when clinically appropriate after evaluation — with the form and dose tailored to your symptoms, history, and labs.
Learn about Women's Health →Peptide therapy moved from niche bodybuilding circles to mainstream wellness marketing in roughly five years. Not all of the claims kept up with the evidence. Here's what the published research actually says about each of the four compounds Reach Peak Life's longevity protocols currently include — separated from the social-media noise. Some of these have strong data behind them. Some have promising preliminary data. We've organized them honestly by what the literature supports.
A peptide is a short chain of amino acids — typically fewer than 50 — that signals specific receptors or processes in the body. The body produces hundreds of endogenous peptides constantly; insulin and oxytocin are familiar examples. Therapeutic peptides are either synthetic versions of natural peptides, or analogs designed to bind the same receptors with longer half-lives or specific tissue targeting.
Peptides are not steroids and they are not "supplements" in the FDA sense. The compounds discussed below are prepared by 503A compounding pharmacies under prescription from a licensed provider; they are not FDA-approved as commercial products.
PT-141, also called bremelanotide, is a melanocortin-receptor agonist that acts centrally — in the brain — to influence sexual desire and arousal, rather than acting on blood flow the way PDE5 inhibitors (sildenafil, tadalafil) do. This is a meaningfully different mechanism: it targets the upstream signaling of desire rather than the downstream plumbing of an erection.
Unlike most peptides in the wellness space, PT-141 has a real regulatory precedent. Its active ingredient, bremelanotide, was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, under the brand discussed in our footer disclosures. Use in men, and use of compounded preparations, is off-label — but the existence of an approved product means the molecule has cleared human safety and efficacy review for at least one indication, which is more than can be said for most peptides marketed for libido. It is taken as-needed before activity rather than on a daily schedule, and is available as a compounded preparation through licensed 503A/503B pharmacies. Common side effects in trials included nausea, flushing, and transient blood-pressure elevation, which is why provider evaluation matters before use.
Sermorelin is a synthetic analog of growth hormone releasing hormone (GHRH). It stimulates the pituitary to release the body's own growth hormone in a natural pulsatile pattern, rather than introducing exogenous GH directly. It was FDA-approved in 1990 for pediatric growth hormone deficiency, then withdrawn for commercial reasons (not safety) in 2008; it remains available through compounding pharmacies.
Adult use for sleep quality, recovery, and body composition is off-label but has decades of clinical use behind it. The evidence base for adult longevity outcomes specifically is limited — most adult studies focus on body composition and quality-of-life endpoints over 6–12 months, not multi-decade outcomes. The safety profile is well-characterized.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that drops with age and is required for several longevity-relevant pathways including sirtuin activation. The Sinclair lab's work has been the major popular driver of interest in NAD+ supplementation.
Direct IV NAD+ has variable bioavailability and the systemic effects are still being characterized. Oral precursors — NMN and NR — have more controlled human studies showing reliable elevation of blood NAD+ levels, though whether that translates to clinical longevity outcomes is still an open question. The honest answer here is: the underlying biology is interesting, the clinical outcomes data is preliminary, and 5–10 years of further research will probably clarify the picture significantly.
Glutathione is the body's primary intracellular antioxidant. Levels drop with age, oxidative stress, and several specific pathologies. The case for glutathione's biological importance is unambiguous; the case for supplementation is more nuanced.
Oral glutathione has poor bioavailability — most of it is broken down in the gut. Liposomal and IV forms get higher blood levels, but whether elevated blood glutathione meaningfully raises intracellular glutathione (where it actually does its work) is contested. The strongest clinical evidence is in specific pathologies (acetaminophen overdose, certain liver diseases) rather than general wellness. Pre-cursors like N-acetylcysteine often have stronger evidence than glutathione itself.
A reasonable framework, drawn from how the evidence actually stratifies:
None of these are appropriate to start without a provider evaluation. None are substitutes for the foundational levers (sleep, exercise, body composition, blood work). And none of them have the multi-decade human longevity outcome data that lifestyle interventions have. They are tools, not magic.
Reach Peak Life's longevity protocols include the compounds discussed here, prescribed by independent providers when appropriate for the individual's goals and labs. We're upfront about which compounds have strong evidence and which are based on emerging data, and we don't market any of them as cures or guarantees.
Provider-supervised peptide and longevity protocols. Compound selection is matched to your goals and labs — not a one-size-fits-all stack.
Learn about Longevity →An A1c of 5.7 lands you in the "pre-diabetes" category — a label that often gets dismissed as not a real diagnosis. The label is misleading. The disease process driving A1c upward is already underway by the time you cross 5.7. The good news: this is the window where the trajectory is most responsive to intervention.
Hemoglobin A1c reflects the percentage of your red blood cells that have glucose attached to them. Because red blood cells live about 120 days, A1c gives you an average of your blood sugar over the past 2–3 months — much more useful than a single fasting reading, which only tells you what your glucose was that morning.
A1c of 5.7 corresponds to an estimated average glucose around 117 mg/dL. For context: a healthy non-diabetic adult typically averages somewhere in the 80–105 range. So 5.7 is not a "normal" reading that's been arbitrarily reclassified as concerning — it reflects average glucose meaningfully higher than the metabolically healthy population.
The American Diabetes Association defines:
The thresholds aren't arbitrary. They're drawn from large prospective cohorts that tracked who progressed to diabetes and who developed diabetes-related complications (retinopathy, nephropathy, cardiovascular events). The 5.7 threshold is roughly where the curves start bending — risk of progression climbs measurably above this point.
The Diabetes Prevention Program (DPP, Knowler 2002) — one of the largest interventional trials in this space — showed that adults in the pre-diabetic range had roughly an 11% per year conversion rate to type 2 diabetes without intervention. That compounds: roughly half progress to full diabetes within 5–7 years if nothing changes.
The dominant process is insulin resistance: your cells respond less efficiently to insulin, so your pancreas compensates by secreting more of it. For years, this works — fasting glucose stays normal even as insulin demand rises. The pancreas is doing extra work to keep the system in range.
Eventually the compensation starts to fail. Beta cell function declines (some of it irreversibly), insulin output can no longer keep up with resistance, and fasting glucose starts to rise. By the time you have a "real" diabetes A1c (≥ 6.5), beta cell function has typically already lost 50% of its capacity — and most of that loss is permanent.
That's why the pre-diabetic window matters: it's when you can still meaningfully alter the trajectory of beta cell health, not just manage symptoms after the damage is done.
The DPP and subsequent trials are unusually clear on what works:
A single A1c in the 5.7–6.4 range is worth a conversation with your primary care provider, ideally one that includes: a fasting insulin level (to assess insulin resistance directly via HOMA-IR), a fasting lipid panel, blood pressure check, and a frank conversation about what your individual modifiable risk factors are. Your PCP can also identify whether a referral to an endocrinologist or registered dietitian is appropriate.
This is the kind of finding where early action genuinely changes outcomes — and where waiting until the next annual physical to "see if it goes up" is often the wrong call.
Reach Peak Life's lab panels include A1c with reference values appropriate for adult metabolic health. The Longevity Score calculator includes A1c in its scoring engine and flags values in the 5.7+ range as part of the metabolic-risk screen. As always: a Reach Peak Life score is not a substitute for clinical evaluation, and significant findings should be discussed with your PCP.
A1c, fasting insulin, lipid panel, and CBC — the markers that together describe metabolic trajectory. Order direct, no clinic visit required.
Browse Lab Panels →
